灌注影像筛选下卒中发病6至16小时的血栓切除术
DEFUSE 3 是多中心、随机、开放标签、盲法终点评估试验,纳入最后已知良好状态后6至16小时、近端大脑中动脉或颈内动脉闭塞、初始梗死体积小于70 ml、灌注影像缺血组织体积与梗死体积比值≥1.8的患者。182例随机分入血管内治疗联合标准药物治疗组(92例)或单用标准药物治疗组(90例),试验因疗效提前终止。联合治疗组90天改良Rankin量表分布呈有利偏移(OR 2.77,P<0.001),功能独立(mRS 0–2分)比例45% vs 17%(P<0.001),90天死亡率14% vs 26%(P=0.05),症状性颅内出血7% vs 4%(P=0.75),严重不良事件43% vs 53%(P=0.18)。
要点
- 发病6至16小时、近端大脑中动脉或颈内动脉闭塞、初始梗死体积<70 ml且灌注缺血/梗死体积比值≥1.8的患者,血栓切除术联合标准药物治疗可改善90天功能结局(OR 2.77,P<0.001)。
- 联合治疗组90天功能独立(mRS 0–2分)比例为45%,单用标准药物治疗组为17%(P<0.001)。
- 90天死亡率联合治疗组14%、单用标准药物治疗组26%(P=0.05);症状性颅内出血分别为7%和4%(P=0.75),严重不良事件分别为43%和53%(P=0.18)。
- 试验在美国38个中心进行,因疗效提前终止,共182例随机(血管内治疗组92例、药物治疗组90例)。
适用人群与场景
- 最后已知良好状态后6至16小时的卒中患者。
- 近端大脑中动脉或颈内动脉闭塞。
- 初始梗死体积小于70 ml。
- 灌注影像上缺血组织体积与梗死体积比值≥1.8。
诊断标准与关键阈值
- 初始梗死体积小于70 ml。
- 灌注影像缺血组织体积与梗死体积比值≥1.8。
- 功能独立定义为改良Rankin量表评分0至2分。
处置流程与药物剂量
- 血管内治疗(血栓切除术)联合标准药物治疗。
- 标准药物治疗。
研究设计与关键结果
- 多中心、随机、开放标签、盲法终点评估试验,在美国38个中心进行,因疗效提前终止,共182例随机(血管内治疗组92例、药物治疗组90例)。
- 主要终点90天改良Rankin量表分布呈有利偏移(OR 2.77,P<0.001)。
- 90天功能独立(mRS 0–2分)比例:血管内治疗组45% vs 药物治疗组17%(P<0.001)。
- 90天死亡率:血管内治疗组14% vs 药物治疗组26%(P=0.05)。
- 症状性颅内出血:血管内治疗组7% vs 药物治疗组4%(P=0.75),无显著组间差异。
- 严重不良事件:血管内治疗组43% vs 药物治疗组53%(P=0.18),无显著组间差异。
证据类型、等级与局限
- 随机对照试验(DEFUSE 3,NCT02586415),由美国国家神经疾病与卒中研究所资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对最后已知良好状态后6至16小时、近端大脑中动脉或颈内动脉闭塞、初始梗死体积小于70 ml且灌注影像缺血/梗死体积比值≥1.8的患者,血管内血栓切除术联合标准药物治疗比单用标准药物治疗获得更好的90天功能结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Thrombectomy is currently recommended for eligible patients with stroke who are treated within 6 hours after the onset of symptoms.
METHODS: We conducted a multicenter, randomized, open-label trial, with blinded outcome assessment, of thrombectomy in patients 6 to 16 hours after they were last known to be well and who had remaining ischemic brain tissue that was not yet infarcted. Patients with proximal middle-cerebral-artery or internal-carotid-artery occlusion, an initial infarct size of less than 70 ml, and a ratio of the volume of ischemic tissue on perfusion imaging to infarct volume of 1.8 or more were randomly assigned to endovascular therapy (thrombectomy) plus standard medical therapy (endovascular-therapy group) or standard medical therapy alone (medical-therapy group). The primary outcome was the ordinal score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability) at day 90.
RESULTS: The trial was conducted at 38 U.S. centers and terminated early for efficacy after 182 patients had undergone randomization (92 to the endovascular-therapy group and 90 to the medical-therapy group). Endovascular therapy plus medical therapy, as compared with medical therapy alone, was associated with a favorable shift in the distribution of functional outcomes on the modified Rankin scale at 90 days (odds ratio, 2.77; P<0.001) and a higher percentage of patients who were functionally independent, defined as a score on the modified Rankin scale of 0 to 2 (45% vs. 17%, P<0.001). The 90-day mortality rate was 14% in the endovascular-therapy group and 26% in the medical-therapy group (P=0.05), and there was no significant between-group difference in the frequency of symptomatic intracranial hemorrhage (7% and 4%, respectively; P=0.75) or of serious adverse events (43% and 53%, respectively; P=0.18).
CONCLUSIONS: Endovascular thrombectomy for ischemic stroke 6 to 16 hours after a patient was last known to be well plus standard medical therapy resulted in better functional outcomes than standard medical therapy alone among patients with proximal middle-cerebral-artery or internal-carotid-artery occlusion and a region of tissue that was ischemic but not yet infarcted. (Funded by the National Institute of Neurological Disorders and Stroke; DEFUSE 3 ClinicalTrials.gov number, NCT02586415 .).
参考来源
- Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018. PMID: 29364767. doi:10.1056/NEJMoa1713973
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。